Advancements in the field and rising interest among pharmaceutical researchers have led to the development of
new molecules with enhanced therapeutic activity. Design of new drugs which can target a particular pathway and/or explore
novel targets is of immense interest to ocular pharmacologists worldwide. Delivery of suitable pharmacologically
active agents at proper dose (within the therapeutic window) to the target tissues without any toxicity to the healthy ocular
tissues still remain an elusive task. Moreover, the presence of static and dynamic barriers to drug absorption including the
corneal epithelium (lipophilic), corneal and scleral stroma (hydrophilic), conjunctival lymphatics, choroidal vasculature
and the blood-ocular barriers also pose a significant challenge for achieving therapeutic drug concentrations at the target
site. Although many agents are currently available, new compounds are being introduced for treating various ocular diseases.
Deeper understanding of the etiology and complex mechanisms associated with the disease condition would aid in
the development of potential therapeutic candidates. Novel small molecules as well as complex biotechnology derived
macromolecules with superior efficacy, safety and tolerability are being developed. Therefore, this review article provides
an overview of existing drugs, treatment options, advances in emerging therapeutics and related recent patents for the
treatment of ocular disorders such as glaucoma, age related macular degeneration (AMD) and uveitis.